Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

272.41 +0.72 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
53 54 Next >
Analyst Expectations For Amgen's Future
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to... 
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron filed an appeal after a court's decision, which was issued under seal. 
Via Benzinga
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
What the Options Market Tells Us About Amgen
Via Benzinga
Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN)
NASDAQ:AMGN Shows Potential for a Breakout. 
Via Chartmill
2 Weight-Loss Stocks That Could Rocket Higher This Year
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished. 
Via The Motley Fool
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. 
Via Investor's Business Daily
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
These two stocks could be rivals in the intense GLP-1 space in the future. 
Via The Motley Fool
Can These 5 Assets Skyrocket Your Portfolio?
Are Verizon, Amazon, Cisco, Amgen, and the S&P Biotech Bull 3X Shares ETF poised to make your portfolio skyrocket? In this video, I take a closer look. 
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
Where Will Amgen Be in 5 Years?
There are plenty of ongoing positive developments with the biotech giant. 
Via The Motley Fool
Behind the Scenes of Amgen's Latest Options Trends
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Amgen Unusual Options Activity For August 29
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Bull Market Strengthened, Let The Naysayers Say Nay...
Being able to recite the potential problems in the world does not make you a good investor. 
Via Talk Markets
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500
Growth-oriented businesses can make excellent additions to a well-diversified portfolio. 
Via The Motley Fool
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market. 
Via The Motley Fool
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. 
Via Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
The results are also promising for the next-generation version of that drug. 
Via Investor's Business Daily
Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters.
The current leadership in the stock market is clearly not tech, or the Magnificent 7. 
Via Talk Markets
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Patchy But Still Bullish
Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations. 
Via Talk Markets
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Jason Snipe of Odyssey Capital Advisors likes Intuit Inc., after the company beat on the top and bottom lines, but missed on guidance. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.